6 Top Gainers In Healthcare Sector (AMRN, DOVA, IMUX…)

The following are some of today’s top gainers in the pharma/biotech sector.

1. Oasmia Pharmaceutical AB (publ) (OASM)

Oasmia Pharmaceutical develops and sells new generations of drugs in the field of human and veterinary oncology.

Gained 29.91% to close Tuesday’s (July 2) trading at $1.45.

News: No news

Recent event:

On June 28, 2019, the Company reported financial results for the fourth quarter ended April 30, 2019.

Net loss after tax widened to TSEK 48,672 in the recent fourth quarter compared to TSEK 32,086 in the fourth quarter of the previous year. Loss per share was SEK 0.23 in the fourth quarter of fiscal 2019 compared to SEK 0.18 in the fourth quarter the previous year.

Consolidated net sales amounted to TSEK 266 in the fourth quarter of 2019 compared to TSEK 843 in the fourth quarter of the prior year.

2. Corvus Pharmaceuticals Inc. (CRVS)

Corvus Pharma is a clinical-stage biopharmaceutical company developing precisely targeted oncology therapies.

Gained 20.96% to close Tuesday’s trading at $5.02.

News: No news

Clinical Trials & Near-term Catalysts:

— A phase 1/1b study of CPI-818 in patients with T-cell lymphomas is underway, with initial data from the study expected in late 2019.
— Enrollment of patients is ongoing in an amended Phase 1b/2 clinical trial of Ciforadenant in combination with Genentech’s Tecentriq in renal cell cancer.
— Enrollment is underway in a Phase 1b/2 trial of Ciforadenant in combination with Tecentriq in patients with non-small cell lung cancer.
— A phase 1/1b clinical trial evaluating CPI-006 as a single agent and in combination with either Ciforadenant or Pembrolizumab is underway.
— A phase 1/1b study of CPI-818 in patients with several types of T-cell lymphomas, including peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL) and others is ongoing.

3. Amarin Corporation plc (AMRN)

Amarin is a pharmaceutical company developing therapeutics for the treatment of cardiovascular diseases in the United States. The Company’s lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Gained 16.27% to close Tuesday’s trading at $22.37.

News: Based on estimated total revenue results for the first half of 2019 which exceeded prior expectations, the Company has increased its revenue guidance for 2019 to range between $380 and $420 million, up from its earlier forecast of $350 million.

Near-term Catalyst:

A supplemental new drug application for Vascepa seeking cardiovascular risk reduction indication is under priority review by the FDA, with a decision date set for September 28, 2019.

4. Karyopharm Therapeutics Inc. (KPTI)

Gained 15.55% to close Tuesday’s trading at $6.54.

News: No news

Near-term Catalyst:

The FDA decision on Karyopharm’s New Drug Application seeking accelerated approval for Selinexor in combination with Dexamethasone as a new treatment for patients with triple class refractory multiple myeloma is expected on July 6, 2019.

In February of this year, an FDA panel, which reviewed the Selinexor NDA voted 8 to 5 against the accelerated approval, and recommended that the approval decision for Selinexor should be delayed until the results of a phase III study, dubbed BOSTON, are available.

The phase III BOSTON study is underway, and top-line data is expected by the end of 2019 or 2020.

5. Dova Pharmaceuticals Inc. (DOVA)

Gained 13.36% to close Tuesday’s trading at $16.21.

News: No news

Recent event:

On June 27, 2019, the FDA approved the Company’s drug DOPTELET for yet another indication – i.e., for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

DOPTELET was first approved in the U.S. for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure on May 21, 2018, and was launched on June 4, 2018. Net product sales from DOPTELET were $7.7 million for the full year ended December 31, 2018.

On June 25 2019, the European Commission approved DOPTELET for the treatment of severe thrombocytopenia in adult patients with CLD who are scheduled to undergo an invasive procedure.

6. Immunic Inc. (IMUX)

Immunic is a clinical-stage biopharmaceutical company developing oral immunology therapies for chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis.

Gained 11.61% to close Tuesday’s trading at $12.59.

News: No news

Clinical Trials & Near-term Catalysts:

— A phase II study of IMU-838 for ulcerative colitis, dubbed CALDOSE-1, is underway, with top-line data expected to be available in the first quarter of 2021.
— A phase II study of IMU-838 for relapsing-remitting multiple sclerosis, dubbed EMPhASIS, is ongoing, with topline data anticipated to be available during the third quarter of 2020.
— A phase II study of IMU-838 in Crohn’s disease, dubbed CALDOSE-2, is expected to begin during the second half of 2019.
— A phase I trial of IMU-935 in healthy volunteers and psoriasis patients is expected to begin during September 2019.
— A phase I trial of IMU-856 is expected to begin in H1 2020. IMU-856 targets inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease.

Source: Read Full Article